Five Prime Therapeutics Inc (FPRX) to Post Q1 2018 Earnings of ($0.55) Per Share, Leerink Swann Forecasts
Five Prime Therapeutics Inc (NASDAQ:FPRX) – Equities research analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for Five Prime Therapeutics in a note issued to investors on Wednesday. Leerink Swann analyst M. Schmidt anticipates that the biotechnology company will post earnings per share of ($0.55) for the quarter. Leerink Swann also issued estimates for Five Prime Therapeutics’ Q2 2018 earnings at ($1.33) EPS, Q3 2018 earnings at ($1.33) EPS, Q4 2018 earnings at ($1.39) EPS, FY2018 earnings at ($4.61) EPS, FY2019 earnings at ($5.55) EPS and FY2020 earnings at ($5.01) EPS.
Other equities analysts have also recently issued research reports about the stock. Nomura cut their target price on shares of Five Prime Therapeutics from $94.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, February 28th. BidaskClub upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 31st. BMO Capital Markets lifted their price target on shares of Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a report on Tuesday, November 7th. Finally, Royal Bank of Canada lifted their price target on shares of Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, November 6th. Three equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. Five Prime Therapeutics currently has an average rating of “Hold” and an average price target of $47.20.
Hedge funds and other institutional investors have recently modified their holdings of the company. Teacher Retirement System of Texas purchased a new stake in shares of Five Prime Therapeutics during the fourth quarter worth about $221,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Five Prime Therapeutics during the third quarter worth about $223,000. MetLife Investment Advisors LLC purchased a new stake in shares of Five Prime Therapeutics during the fourth quarter worth about $294,000. Dupont Capital Management Corp purchased a new stake in shares of Five Prime Therapeutics during the third quarter worth about $341,000. Finally, Voya Investment Management LLC grew its holdings in shares of Five Prime Therapeutics by 9.5% during the second quarter. Voya Investment Management LLC now owns 12,594 shares of the biotechnology company’s stock worth $379,000 after buying an additional 1,097 shares in the last quarter. Institutional investors and hedge funds own 73.98% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/03/04/five-prime-therapeutics-inc-fprx-to-post-q1-2018-earnings-of-0-55-per-share-leerink-swann-forecasts.html.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.